Myelodysplastic syndrome with isolated del(5q)

ICD-O-2 Morphology

Effective 1992 - 2000

ICD-O-3 Morphology

9986/3: Myelodysplastic syndrome associated with isolated del (5q)
Effective 2001 and later


for cases diagnosed 2001 and later

Primary Site(s)

Primary site must be bone marrow (C421)

Abstractor Notes

MDS with associated del(5q) is an MDS involves that blood and bone marrow.

For MDS diseases (9980, 9982, 9983, 9985, 9986, 9989, 9991, 9992, 9993), abstracting each of the subtypes would result in over-counting of the diseases.
1. Code only the first subtype that is diagnosed.
2. Do not change the histology code or create a new abstract for any subsequent specific MDS subtypes

Recently the thalidomide analog lenalidomide has been shown to benefit MDS patients. Transfusion independence was achieved in two-thirds of patients.

Diagnostic Confirmation

This histology can only be determined by positive genetics and/or immunophenotyping, diagnostic confirmation will always be 3.


Not Applicable

Module Rule


Alternate Names

5q minus syndrome
MDS with 5q deletion
Myelodysplastic syndrome associated with isolated del(5q)
Myelodysplastic syndrome with 5q deletion (5q-syndrome)


Bone marrow dysplasia showing refractory macrocytic anemia with oval macrocytes and nonlobulated megakaryocytes. 75% of patients have increased cellularity of marrow. One third of patients have chromosomal abnormality that consists of deletion of the long arm of chromosome 5 (5q). Marrow blasts <5%.
Platelet count normal to elevated
No Auer rods
Normal to increased megakaryocytes

Definitive Diagnostic Methods

Bone marrow biopsy
Genetic testing

Genetics Data

Deletion between bands q31 and q33 on chromosome 5




Hematologic Transplant and/or Endocrine Procedures

Transformations from


Corresponding ICD-9 Codes

238.74 Myelodysplastic syndrome with 5q deletion

Corresponding ICD-10 Codes

D46.7 Other myelodysplastic syndromes

Corresponding ICD-10-CM Codes (U.S. only)

D46.C Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality (effective October 01, 2015)

Signs and Symptoms

Easy bruising or bleeding
Petechiae (flat, pinpoint spots under the skin caused by bleeding)
Shortness of breath
Skin paler than usual
Weakness or feeling tired

Diagnostic Exams

Blood chemistry studies
Cytogenetic analysis
FISH (flourescence in situ hybridzation)
Flow cytometry
Peripheral blood smear

Progression and Transformation

<10% of cases transform to AML

Epidemiology and Mortality

Age: 67 years median age
Sex: female predominance
Survival: 145 month median survival


Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Myelodysplastic syndromes
Pages: 115-16

International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes

National Cancer Institute
Section: General Information About Myelodysplastic Syndromes